193 related articles for article (PubMed ID: 12520528)
1. A new active vitamin D analog, ED-71, causes increase in bone mass with preferential effects on bone in osteoporotic patients.
Kubodera N; Tsuji N; Uchiyama Y; Endo K
J Cell Biochem; 2003 Feb; 88(2):286-9. PubMed ID: 12520528
[TBL] [Abstract][Full Text] [Related]
2. ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis.
Uchiyama Y; Higuchi Y; Takeda S; Masaki T; Shira-Ishi A; Sato K; Kubodera N; Ikeda K; Ogata E
Bone; 2002 Apr; 30(4):582-8. PubMed ID: 11934649
[TBL] [Abstract][Full Text] [Related]
3. Rationale for active vitamin D and analogs in the treatment of osteoporosis.
Nishii Y
J Cell Biochem; 2003 Feb; 88(2):381-6. PubMed ID: 12520540
[TBL] [Abstract][Full Text] [Related]
4. Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone.
Harada S; Mizoguchi T; Kobayashi Y; Nakamichi Y; Takeda S; Sakai S; Takahashi F; Saito H; Yasuda H; Udagawa N; Suda T; Takahashi N
J Bone Miner Res; 2012 Feb; 27(2):461-73. PubMed ID: 22052469
[TBL] [Abstract][Full Text] [Related]
5. The role of the serum vitamin D binding protein in the actions of the vitamin D analog eldecalcitol (ED-71) on bone and mineral metabolism.
Brown AJ; Zhang F; Cooke NE; Ritter CS
Calcif Tissue Int; 2013 Aug; 93(2):163-71. PubMed ID: 23689467
[TBL] [Abstract][Full Text] [Related]
6. Eldecalcitol and calcitriol stimulates 'bone minimodeling,' focal bone formation without prior bone resorption, in rat trabecular bone.
Saito H; Takeda S; Amizuka N
J Steroid Biochem Mol Biol; 2013 Jul; 136():178-82. PubMed ID: 23069645
[TBL] [Abstract][Full Text] [Related]
7. [ED-71].
Endo K; Tsuji N
Clin Calcium; 2002 Aug; 12(8):1152-6. PubMed ID: 15775413
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic agents for disorders of bone and calcium metabolism: ED-71].
Tsuji N; Takahashi F
Clin Calcium; 2007 Jan; 17(1):72-9. PubMed ID: 17211096
[TBL] [Abstract][Full Text] [Related]
9. Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: a comparison with alfacalcidol and alendronate.
Sugimoto M; Futaki N; Harada M; Kaku S
Bone; 2013 Jan; 52(1):181-8. PubMed ID: 23041510
[TBL] [Abstract][Full Text] [Related]
10. 1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats.
Weber K; Goldberg M; Stangassinger M; Erben RG
J Bone Miner Res; 2001 Apr; 16(4):639-51. PubMed ID: 11315991
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional and potent roles of the 3-hydroxypropoxy group provide eldecalcitol's benefit in osteoporosis treatment.
Ono Y
J Steroid Biochem Mol Biol; 2014 Jan; 139():88-97. PubMed ID: 24139874
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis.
Richy F; Schacht E; Bruyere O; Ethgen O; Gourlay M; Reginster JY
Calcif Tissue Int; 2005 Mar; 76(3):176-86. PubMed ID: 15692726
[TBL] [Abstract][Full Text] [Related]
13. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial.
Matsumoto T; Miki T; Hagino H; Sugimoto T; Okamoto S; Hirota T; Tanigawara Y; Hayashi Y; Fukunaga M; Shiraki M; Nakamura T
J Clin Endocrinol Metab; 2005 Sep; 90(9):5031-6. PubMed ID: 15972580
[TBL] [Abstract][Full Text] [Related]
14. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
Reginster JY; Lecart MP; Richy F
J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
[TBL] [Abstract][Full Text] [Related]
15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
16. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis.
Jones G; Hogan DB; Yendt E; Hanley DA
CMAJ; 1996 Oct; 155(7):955-61. PubMed ID: 8837546
[TBL] [Abstract][Full Text] [Related]
17. [Eldecalcitol (ED-71)].
Endo I; Matsumoto T
Clin Calcium; 2011 Jan; 21(1):53-8. PubMed ID: 21187594
[TBL] [Abstract][Full Text] [Related]
18. Alfacalcidol reduces accelerated bone turnover in elderly women with osteoporosis.
Shiraki M; Fukuchi M; Kiriyama T; Okamoto S; Ueno T; Sakamoto H; Nagai T
J Bone Miner Metab; 2004; 22(4):352-9. PubMed ID: 15221494
[TBL] [Abstract][Full Text] [Related]
19. Syntheses and preventive effects of analogues related to 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3 (ED-71) on bone mineral loss in ovariectomized rats.
Ono Y; Kawase A; Watanabe H; Shiraishi A; Takeda S; Higuchi Y; Sato K; Yamauchi T; Mikami T; Kato M; Tsugawa N; Okano T; Kubodera N
Bioorg Med Chem; 1998 Dec; 6(12):2517-23. PubMed ID: 9925307
[TBL] [Abstract][Full Text] [Related]
20. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
Ringe JD; Faber H; Fahramand P; Schacht E
J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
